Research Article
Association of CYP2A6 polymorphisms with S-1 plus docetaxel therapy outcomes in metastatic gastric cancer
Published Online:15 Jul 2009https://doi.org/10.2217/pgs.09.48
Abstract
Aims: S-1, an oral fluoropyrimidine, contains tegafur, which is converted to 5-fluorouracil mainly by CYP2A6. We evaluated the association between CYP2A6 polymorphisms and treatment outcome in metastatic gastric cancer patients treated with S-1 plus docetaxel. Materials & methods: Chemonaive patients received S-1 40 mg/m2 twice daily on days 1–14 and docetaxel 35 mg/m2 on days 1 and 8 of a 3-week cycle. We analyzed the wild-type (W) allele (CYP2A6*1) and four variant (V) alleles that abolish or reduce enzyme activity (CYP2A6*4, *7, *9 and *10). A total of 50 patients were enrolled. Results: The genotype frequencies were as follows: W/W (n = 14, 28%), W/V (n = 26, 52%) and V/V (n = 10, 20%). Patients having fewer variant alleles had significantly better response rates (W/W vs W/V vs V/V = 79 vs 65 vs 30%; p = 0.04) and median progression-free survival (W/W vs W/V vs V/V = 8.1 vs 6.9 vs 3.1 months; p = 0.0009). Conclusion: Our findings showed that the CYP2A6 genotype correlated with the treatment efficacy of S-1-based chemotherapy in previously untreated metastatic gastric cancer patients.
Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest
Bibliography
- 1 Koizumi W, Narahara H, Hara T et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a Phase III trial. Lancet Oncol.9(3),215–221 (2008).
- 2 Boku N, Yamamoto S, Shirao K et al.: Randomized Phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). J. Clin. Oncol.25(18S),200S (2007) (Abstract LBA4513).
- 3 Sakuramoto S, Sasako M, Yamaguchi T et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N. Engl. J. Med.357(18),1810–1820 (2007).
- 4 Yamada Y, Tahara M, Miya T et al.: Phase I/II study of oxaliplatin with oral S-1 as first-line therapy for patients with metastatic colorectal cancer. Br. J. Cancer98(6),1034–1038 (2008).
- 5 Ichinose Y, Yoshimori K, Sakai H et al.: S-1 plus cisplatin combination chemotherapy in patients with advanced non-small cell lung cancer: a multi-institutional Phase II trial. Clin. Cancer Res.10(23),7860–7864 (2004).
- 6 Saek T, Takashima S, Sano M et al.: A Phase II study of S-1 in patients with metastatic breast cancer – a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group. Breast Cancer11(2),194–202 (2004).
- 7 Harada K, Sato M, Ueyama Y et al.: Multi-institutional Phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs19(1),85–90 (2008).
- 8 Shirasaka T, Shimamato Y, Ohshimo H et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs7(5),548–557 (1996).
- 9 Tatsumi K, Fukushima M, Shirasaka T, Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn. J. Cancer Res.78(7),748–755 (1987).
- 10 Shirasaka T, Shimamoto Y, Fukushima M: Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res.53(17),4004–4009 (1993).
- 11 Ajani JA, Faust J, Ikeda K et al.: Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol.23(28),6957–6965 (2005).
- 12 Koizumi W, Tanabe S, Saigenji K et al.: Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br. J. Cancer89(12),2207–2212 (2003).
- 13 Lee JL, Kang HJ, Kang YK et al.: Phase I/II study of 3-week combination of S-1 and cisplatin chemotherapy for metastatic or recurrent gastric cancer. Cancer Chemother. Pharmacol.61(5),837–845 (2007).
- 14 van Groeningen CJ, Peters GJ, Schornagel JH et al.: Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J. Clin. Oncol.18(14),2772–2779 (2000).
- 15 Jeung HC, Rha SY, Kim HK et al.: Multi-institutional Phase II study of S-1 monotherapy in advanced gastric cancer with pharmacokinetic and pharmacogenomic evaluations. Oncologist12(5),543–554 (2007).
- 16 Hirata K, Horikoshi N, Aiba K et al.: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin. Cancer Res.5(8),2000–2005 (1999).
- 17 Ikeda K, Yoshisue K, Matsushima E et al.: Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin. Cancer Res.6(11),4409–4415 (2000).▪ CYP2A6 is a principal enzyme responsible for the bioactivation process of tegafur in human liver microsomes.
- 18 Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF: Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenet. Genomics15(3),189–192 (2005).
- 19 Kwon JT, Nakajima M, Chai S et al.: Nicotine metabolism and CYP2A6 allele frequencies in Koreans. Pharmacogenetics11(4),317–323 (2001).
- 20 Nakajima M, Fukami T, Yamanaka H et al.: Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin. Pharmacol. Ther.80(3),282–297 (2006).
- 21 Park SR, Kim HK, Kim CG et al.: Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma. Br. J. Cancer98(8),1305–1311 (2008).
- 22 Therasse P, Arbuck SG, Eisenhauer EA et al.: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst.92(3),205–216 (2000).
- 23 Fukami T, Nakajima M, Sakai H, McLeod HL, Yokoi T: CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele. Pharmacogenomics J.6(6),401–412 (2006).
- 24 Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF: Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics14(9),615–626 (2004).
- 25 Fujita K, Yamamoto W, Endo S et al.: CYP2A6 and the plasma level of 5-chloro-2,4-dihydroxipyridine are determinants of the pharmacokinetic variability of tegafur and 5-fluorouracil, respectively, in Japanese patients with cancer given S-1. Cancer Sci.99(5),1049–1054 (2008).▪▪ Oral clearance of tegafur of S-1 was associated with the CYP2A6 genotype. The oral clearance of tegafur seen in patients with the two-variant alleles were significantly lower than those in wild-type and the one-variant allele.
- 26 Kaida Y, Inui N, Suda T, Nakamura H, Watanabe H, Chida K: The CYP2A6*4 allele is determinant of S-1 pharmacokinetics in Japanese patients with non-small-cell lung cancer. Clin. Pharmacol. Ther.83(4),589–594 (2008).▪▪ Patients with the CYP2A6*4 allele had a significantly higher area under the curve for tegafur of S-1 and lower maximum plasma concentration for 5-FU than patients without the CYP2A6*4.
- 27 Bang YJ, Kang WK, Kang YK et al.: Docetaxel 75 mg/m2 is active and well tolerated in patients with metastatic or recurrent gastric cancer: a Phase II trial. Jpn. J. Clin. Oncol.32(7),248–254 (2002).
- 28 Einzig AI, Neuberg D, Remick SC et al.: Phase II trial of docetaxel (Taxotere®) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med. Oncol.13(2),87–93 (1996).
- 29 Sulkes A, Smyth J, Sessa C et al.: Docetaxel (Taxotere®) in advanced gastric cancer: results of a Phase II clinical trial. EORTC Early Clinical Trials Group. Br. J. Cancer70(2),380–383 (1994).
- 30 Ikeda M, Furukawa H, Imamura H et al.: Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function. Cancer Chemother. Pharmacol.50(1),25–32 (2002).
- 31 Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M: Safety evaluation of oral fluoropyrimidine S-1 for short- and long-term delivery in advanced gastric cancer: analysis of 3,758 patients. Cancer Chemother. Pharmacol.61(2),335–343 (2008).
- 32 Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M: Analysis of risk factors for severe adverse effects of oral 5-fluorouracil S-1 in patients with advanced gastric cancer. Gastric Cancer10(2),129–134 (2007).
- 33 Raj GV, Iasonos A, Herr H, Donat SM: Formulas calculating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer. J. Clin. Oncol.24(19),3095–3100 (2006).
- 101 Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee. www.cypalleles.ki.se
- 102 Common toxicity criteria (CTC) Version 2.0 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcv2nom-4-30-99-final3.pdf
